EU member states remains essential. Additionally, under the EU’s MDR and IVDR, products must have adequate labelling that corresponds to their intended use and safety data.

ICH Guidelines: The International Council for Harmonisation (ICH) guidelines remain pivotal in shaping the frameworks for both clinical and market approval processes, particularly with respect to pharmacovigilance and labelling requirements. Notable among these are Q10 (Pharmaceutical Quality System) and E2E (Pharmacovigilance).

Documentation

The documentation that accompanies multi-country packs must be meticulously prepared to satisfy diverse regulatory expectations. Components of this documentation include:

• Labelling Text: Each pack must contain labels that reflect the language, regulatory requirements, and safety information applicable to the market, including the UK and EU.
• Artwork Approvals: Artwork for labels and packaging must undergo a quality control process to ensure alignment with both UK and EU directives. Companies must consistently engage with approved artwork management systems to manage revisions and approvals.
• Product Information Governance: Assuring that the correct product information is disseminated in line with local regulations is vital for compliance. This includes ensuring that both UK and EU regulatory submissions are appropriately documented and justified in any product-specific Information submitted to agencies.

Review/Approval Flow

The review and approval flow for multi-country labelling post-Brexit requires a strategic approach, ensuring timely submission and compliance with varied regulatory jurisdictions:

1. Submission of Packaging Artwork

Companies must prepare and submit the packaging artwork for both UK and EU approvals. This typically involves:

• Preparing dual-language artwork that accommodates English and the respective EU languages as relevant.
• Submitting a request for approval to the respective authorities, such as the MHRA for the UK and the National Competent Authorities (NCAs) in the EU.

2. Assessment Period

The assessment period for approval varies by jurisdiction. The MHRA usually aims for a two-month turnaround for changes, while responses from EU NCAs can vary greatly based on the nature of the submission. During this period, submission quality plays a critical role in minimizing queries and deficiencies.

3. Addressing Questions and Concerns

During the review phase, it is common for agencies to raise questions or concerns related to packaging and labelling insufficiencies. Proactively addressing these concerns promptly can reduce delays in obtaining approvals.

Common Deficiencies

There are several common deficiencies in the documentation process that pharmaceutical companies face in regard to multi-country packs that include the UK:

• Lack of Compliance with National Regulations: Failure to align the labelling with the specific requirements of both the UK and respective EU countries can lead to significant delays.
• Inadequate Justification for Labelling Changes: Companies must ensure they have rational and evidence-based justifications for any changes made to the packaging and the information it conveys.
• Language Requirements: Failing to meet the language requirements of either jurisdiction is a frequent issue. Companies must ensure that the information is clearly communicated in English for the UK market and languages applicable to the EU member states.

Regulatory Affairs-Specific Decision Points

Regulatory Affairs professionals must navigate a series of decision points when managing multi-country packs that include the UK after Brexit. Key decision points include:

1. Variation or New Application

Determining whether a submission should be categorized as a variation versus a new application can impact timelines and requirements significantly:

• Variation: If changes to the label or packaging do not affect the product’s quality, safety, or efficacy, then a variation submission may be sufficient. This is typically the case for updates regarding regulatory requirements and naming conventions.
• New Application: If there are substantial changes that affect the pharmacological classification, efficacy, or safety profile of the product, a new application may be warranted. This typically requires extensive clinical data and additional justification.

2. Bridging Data Justification

In instances where the same product is marketed under different jurisdictional frameworks, the need for bridging data arises. RA professionals must consider:

• Justifying the absence of additional clinical data by providing comprehensive pharmacovigilance data from approved markets where applicable. This can include compiling robust safety reports and previously submitted risk management plans.
• Providing a rationale for relying on historical data, such as data from EU markets, while demonstrating their applicability to support UK submissions.

Interactions with Related Teams

Successful navigation of these regulatory challenges requires extensive collaboration with various stakeholders. Key areas of interaction include:

1. Chemistry, Manufacturing, and Controls (CMC)

CMC teams must work closely with RA teams to ensure that any changes to product formulations or processes are accurately reflected in labelling and packaging, particularly concerning stability data and storage conditions.

2. Clinical Teams

Collaboration with clinical teams provides essential data regarding clinical outcomes and safety profiles which must be accurately communicated in product labelling. The clinical data forms the backbone of Justification for any variations or changes required in product introductions.

3. Pharmacovigilance (PV) and Quality Assurance (QA)

PV teams must ensure that all data reflecting the product’s safety and efficacy are continually updated in line with requirements from the MHRA and EU authorities. QA teams play a critical role in ensuring compliance with both internal and external standards throughout the artwork and labelling processes.

Practical Tips for Documentation and Justifications

To mitigate common compliance issues related to multi-country packs, consider the following tips for effective documentation and justifications:

• Thoroughly Review Regulatory Guidelines: Stay updated on the latest regulatory changes affecting labelling and document requirements from authorities such as the MHRA and the European Medicines Agency (EMA).
• Enhance Internal Communication: Establish open lines of communication between Regulatory Affairs, CMC, Clinical, QA, and PV teams to ensure all regulatory updates and their implications are clearly understood and documented.
• Utilize Artwork and Labelling Management Systems: Implement robust systems for tracking and version controlling artwork changes and approvals to enhance compliance and minimize errors during submissions.

Conclusion

Managing multi-country packs that include the UK after Brexit necessitates a thorough understanding of both UK and EU regulations, careful documentation, and clear communication among various teams. By navigating the complexities of the regulatory landscape effectively, pharmaceutical companies can ensure that they meet both compliance requirements and maintain the integrity of their product information. The right strategies focused on documentation, collaboration, and understanding regulatory nuances are essential for successful outcomes in the evolving pharmaceutical landscape.